Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Francisco Calvo-Iglesias is active.

Publication


Featured researches published by Francisco Calvo-Iglesias.


Revista Espanola De Cardiologia | 2017

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations

Teresa López-Fernández; Ana García; Ana Santaballa Beltrán; Ángel Montero Luis; Ramón García Sanz; Pilar Mazón Ramos; Sonia Velasco del Castillo; Esteban López de Sá y Areses; Manuel Barreiro-Pérez; Rocío Hinojar Baydes; Leopoldo Pérez de Isla; Silvia Cayetana Valbuena López; Regina Dalmau González-Gallarza; Francisco Calvo-Iglesias; Juan José González Ferrer; Antonio Castro Fernández; Eva González-Caballero; Cristina Mitroi; Meritxell Arenas; Juan Antonio Virizuela Echaburu; Pascual Marco Vera; Andrés Íñiguez Romo; Jose Luis Zamorano; Juan Carlos Plana Gómez; José Luis López Sendón Henchel

Improvements in early detection and treatment have markedly reduced cancer-related mortality. However survival not only depends on effectively cure cancer, but prevention, diagnosis and treatment of cancer-related complications is also needed. Cardiovascular toxicity is a widespread problem across many classes of therapeutic schemes, however scientific evidence in the management of cardiovascular complications of onco-hematological patients is scarce, as these patients have been systematically excluded from clinical trials and current recommendations are based on expert consensus. Multidisciplinary teams are mandatory to decrease morbidity and mortality from both cardiotoxicity and cancer itself. An excessive concern for the occurrence of cardiovascular toxicity, can avoid potentially curative therapies, while underestimating this risk, increases long-term mortality of cancer survivors. The objective of this consensus document, developed in collaboration of the Spanish Society of Cardiology, the Spanish Society of Medical Oncology, the Spanish Society of Radiation Oncology and the Spanish Society of Hematology, is to update the necessary concepts and expertise on cardio-onco-hematology that enable its application in daily clinical practice and to promote the development of local multidisciplinary teams, to improve the cardiovascular health of patients with cancer.


World Journal of Cardiology | 2016

Pulmonary vein stenosis: Etiology, diagnosis and management.

Pablo Pazos-López; Cristina García-Rodríguez; Alba Guitián-González; Emilio Paredes-Galán; María Ángel De La Guarda Álvarez-Moure; Marta Rodríguez-Álvarez; José Antonio Baz-Alonso; Elvis Teijeira-Fernández; Francisco Calvo-Iglesias; Andrés Íñiguez-Romo

Pulmonary vein stenosis (PVS) is rare condition characterized by a challenging diagnosis and unfavorable prognosis at advance stages. At present, injury from radiofrequency ablation for atrial fibrillation has become the main cause of the disease. PVS is characterized by a progressive lumen size reduction of one or more pulmonary veins that, when hemodynamically significant, may raise lobar capillary pressure leading to signs and symptoms such as shortness of breath, cough, and hemoptysis. Image techniques (transesophageal echocardiography, computed tomography, magnetic resonance and perfusion imaging) are essential to reach a final diagnosis and decide an appropriate therapy. In this regard, series from referral centers have shown that surgical and transcatheter interventions may improve prognosis. The purpose of this article is to review the etiology, assessment and management of PVS.


International Journal of Cardiology | 2016

The frailty syndrome and mortality among very old patients with symptomatic severe aortic stenosis under different treatments

Carlos Rodríguez-Pascual; Emilio Paredes-Galán; Ana Isabel Ferrero-Martínez; José Antonio Baz-Alonso; Darío Durán-Muñoz; Eva Gonzalez-Babarro; Marcelo Sanmartín; Teresa Parajes; Ivett Torres-Torres; Miguel Piñón-Esteban; Francisco Calvo-Iglesias; Maria Teresa Olcoz-Chiva; Fernando Rodríguez-Artalejo

BACKGROUND The role of frailty as a prognostic factor in non-selected patients with symptomatic severe aortic stenosis (SAS) is still uncertain. This study aims to examine the association between the frailty syndrome and mortality among very old patients with symptomatic SAS, and to assess whether the association varies with the type of SAS treatment. METHODS AND RESULTS Prospective study of 606 patients aged ≥75years with symptomatic SAS, recruited from February 2010 to January 2015, who were followed up through June 2015. At baseline, frailty was defined as having at least three of the following five criteria: muscle weakness, slow gait speed, low physical activity, exhaustion, and unintentional weight loss. Statistical analyses were performed with multivariate Cox regression. At baseline, 49.3% patients were frail. During a mean follow-up of 98weeks, 35.3% of patients died. The hazard ratio (95% confidence interval) of mortality among frail versus non-frail patients was 1.83 (1.33-2.51). The corresponding results were 1.58 (1.09-2.28) among patients under medical treatment, 3.06 (1.25-7.50) in those with transcatheter aortic valve replacement, and 1.97 (0.83-4.67) in those with surgical aortic valve replacement, p for interaction=0.21. When the frailty criteria were considered separately, mortality was also higher among patients with slow gait speed [1.52 (1.05-2.19)] or low physical activity [1.35 (1.00-1.85)]. CONCLUSIONS Frailty is associated with increased mortality among patients with symptomatic SAS, and this association does not vary with the type of SAS treatment. Future studies evaluating the benefits of different treatments in SAS patients should account for baseline frailty.


Revista Espanola De Cardiologia | 2017

Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y 12 Inhibitors in Patients With Acute Coronary Syndrome

Pedro J. Flores-Blanco; Francisco Cambronero-Sánchez; Sergio Raposeiras-Roubín; Emad Abu-Assi; Gunnar Leithold; Rafael Cobas-Paz; Ana I. Rodríguez Serrano; Francisco Calvo-Iglesias; Mariano Valdés; James L. Januzzi; Andrés Íñiguez-Romo; Sergio Manzano-Fernández

INTRODUCTION AND OBJECTIVES Acute coronary syndrome (ACS) guidelines recommend the use of newer P2Y12 inhibitors (prasugrel and ticagrelor) over clopidogrel in patients with moderate-to-high ischemic risk, unless they have an increased bleeding risk. The aim of our study was to assess the GRACE risk score and the CRUSADE bleeding risk score relative to prescription of newer P2Y12 inhibitors at discharge in ACS patients. METHODS Retrospective analysis of a multicenter ACS registry; 3515 consecutive patients were included. The association between risk scores and prescription of newer P2Y12 inhibitors was assessed by binary logistic regression analysis. RESULTS A total of 1021 patients (29%) were treated with prasugrel or ticagrelor. On multivariate analyses, both GRACE (OR per 10 points, 0.89; 95%CI, 0.86-0.92; P < .001) and CRUSADE (OR per 10 points, 0.96; 95%CI, 0.94-0.98; P < .001) risk scores were inversely associated with the use of newer P2Y12 inhibitors. Moreover, other factors not included in these scores (revascularization approach, in-hospital stent thrombosis, major bleeding, and concomitant indication for anticoagulation therapy) also predicted the use of newer P2Y12 inhibitors. CONCLUSIONS New P2Y12 inhibitors were more frequently prescribed among ACS patients with lower CRUSADE bleeding risk. However, an ischemic risk paradox was found, with higher use of these agents in patients with lower ischemic risk based on GRACE risk score estimates. These results underscore the importance of risk stratification to safely deliver optimal therapies.


Revista Espanola De Cardiologia | 2018

Differential Prognostic Impact on Mortality of Myocardial Infarction Compared With Bleeding Severity in Contemporary Acute Coronary Syndrome Patients

Berenice Caneiro-Queija; Emad Abu-Assi; Sergio Raposeiras-Roubín; Sergio Manzano-Fernández; Pedro Flores Blanco; Ángel López-Cuenca; Rafael Cobas-Paz; Miriam Gómez-Molina; José Manuel Rodríguez-Rodríguez; Francisco Calvo-Iglesias; Mariano Valdés-Chávarri; Andrés Íñiguez-Romo

INTRODUCTION AND OBJECTIVES The impact on mortality of myocardial infarction (MI) compared with the specific degree of bleeding severity occurring after discharge in acute coronary syndrome is poorly characterized. Defining this relationship may help to achieve a favorable therapeutic risk-benefit balance. METHODS Using Cox-based shared frailty models, we assessed the relationship between mortality and postdischarge MI and bleeding severity-graded according to Bleeding Academic Research Consortium (BARC)-in 4229 acute coronary syndrome patients undergoing in-hospital coronary arteriography between January 2012 and December 2015. RESULTS Both MI (HR, 5.8; 95%CI, 3.7-9.8) and bleeding (HR, 5.1; 95%CI, 3.6-7.7) were associated with mortality. Myocardial infarction had a stronger impact on mortality than BARC type 2 and 3a bleedings: (RRr, 3.8 and 1.9; P < .05), respectively, but was equivalent to BARC type 3b (RRr, 0.9; P = .88). Mortality risk after MI was significantly lower than after BARC type 3c bleeding (RRr, 0.25; P < .001). Mortality was higher after an MI in patients on dual antiplatelet therapy (DAPT) at the time of the event (HR, 2.9; 95%CI, 1.8-4.5) than in those off-DAPT (HR, 1.5; 95%CI, 0.7-3.4). In contrast, mortality was lower after a bleeding event in patients on-DAPT (HR, 1.6; 95%CI, 1.1-2.6) than in those off-DAPT (HR, 3.2; 95%CI, 1.7-5.8). CONCLUSIONS The differential effect on mortality of a postdischarge MI vs bleeding largely depends on bleeding severity. The DAPT status at the time of MI or bleeding is a modifier of subsequent mortality risk.


Revista Espanola De Cardiologia | 2018

Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome

Sergio Raposeiras-Roubín; Berenice Caneiro Queija; Fabrizio D’Ascenzo; Tim Kinnaird; Sergio Manzano-Fernández; Christian Templin; Lazar Velicki; Ioanna Xanthopoulou; Enrico Cerrato; Giorgio Quadri; Andrea Rognoni; Giacome Boccuzzi; Andrea Montabone; Salma Taha; Alessandro Durante; Sebastiano Gili; Giulia Magnani; Michele Autelli; Alberto Grosso; Pedro Flores Blanco; Alberto Garay; Ferdinando Varbella; Francesco Tomassini; Rafael Cobas Paz; María Cespón Fernández; Isabel Muñoz Pousa; Diego Gallo; Umberto Morbiducci; Alberto Dominguez-Rodriguez; José Antonio Baz-Alonso

INTRODUCTION AND OBJECTIVES The PARIS score allows combined stratification of ischemic and hemorrhagic risk in patients with ischemic heart disease treated with coronary stenting and dual antiplatelet therapy (DAPT). Its usefulness in patients with acute coronary syndrome (ACS) treated with ticagrelor or prasugrel is unknown. We investigated this issue in an international registry. METHODS Retrospective multicenter study with voluntary participation of 11 centers in 6 European countries. We studied 4310 patients with ACS discharged with DAPT with ticagrelor or prasugrel. Ischemic events were defined as stent thrombosis or spontaneous myocardial infarction, and hemorrhagic events as BARC (Bleeding Academic Research Consortium) type 3 or 5 bleeding. Discrimination and calibration were calculated for both PARIS scores (PARISischemic and PARIShemorrhagic). The ischemic-hemorrhagic net benefit was obtained by the difference between the predicted probabilities of ischemic and bleeding events. RESULTS During a period of 17.2 ± 8.3 months, there were 80 ischemic events (1.9% per year) and 66 bleeding events (1.6% per year). PARISischemic and PARIShemorrhagic scores were associated with a risk of ischemic events (sHR, 1.27; 95%CI, 1.16-1.39) and bleeding events (sHR, 1.14; 95%CI, 1.01-1.30), respectively. The discrimination for ischemic events was modest (C index = 0.64) and was suboptimal for hemorrhagic events (C index = 0.56), whereas calibration was acceptable for both. The ischemic-hemorrhagic net benefit was negative (more hemorrhagic events) in patients at high hemorrhagic risk, and was positive (more ischemic events) in patients at high ischemic risk. CONCLUSIONS In patients with ACS treated with DAPT with ticagrelor or prasugrel, the PARIS model helps to properly evaluate the ischemic-hemorrhagic risk.


Revista Espanola De Cardiologia | 2017

Cardio-Onco-Hematología en la práctica clínica. Documento de consenso y recomendaciones

Teresa López-Fernández; Ana García; Ana Santaballa Beltrán; Ángel Montero Luis; Ramón García Sanz; Pilar Mazón Ramos; Sonia Velasco del Castillo; Esteban López de Sá y Areses; Manuel Barreiro-Pérez; Rocío Hinojar Baydes; Leopoldo Pérez de Isla; Silvia Cayetana Valbuena López; Regina Dalmau González-Gallarza; Francisco Calvo-Iglesias; Juan José González Ferrer; Antonio Castro Fernández; Eva González-Caballero; Cristina Mitroi; Meritxell Arenas; Juan Antonio Virizuela Echaburu; Pascual Marco Vera; Andrés Íñiguez Romo; Jose Luis Zamorano; Juan Carlos Plana Gómez; José Luis López Sendón Henchel


Revista Espanola De Cardiologia | 2011

Prognostic Impact of Interventional Approach in Non-ST Segment Elevation Acute Coronary Syndrome in Very Elderly Patients

Iñaki Villanueva-Benito; Itziar Solla-Ruiz; Emilio Paredes-Galán; Óscar Díaz-Castro; Francisco Calvo-Iglesias; José Antonio Baz-Alonso; Andrés Íñiguez-Romo


Revista Portuguesa De Pneumologia | 2018

Effect of beta-blocker dose on mortality after acute coronary syndrome

Sergio Raposeiras-Roubín; Emad Abu-Assi; Berenice Caneiro-Queija; Rafael Cobas-Paz; Lucía Rioboó-Lestón; Cristina García Rodríguez; Cruz Giraldez Lemos; María Blanco Vidal; Beatriz Ogando Guillán; Isabel Pérez Martínez; Emilio Paredes-Galán; Víctor Jimenez-Díaz; José Antonio Baz-Alonso; Francisco Calvo-Iglesias; Andrés Íñiguez-Romo


Revista Espanola De Cardiologia | 2018

Impacto pronóstico diferencial del infarto de miocardio comparado con la gravedad de la hemorragia sobre la mortalidad en pacientes contemporáneos con síndrome coronario agudo

Berenice Caneiro-Queija; Emad Abu-Assi; Sergio Raposeiras-Roubín; Sergio Manzano-Fernández; Pedro Flores Blanco; Ángel López-Cuenca; Rafael Cobas-Paz; Miriam Gómez-Molina; José Manuel Rodríguez-Rodríguez; Francisco Calvo-Iglesias; Mariano Valdés-Chávarri; Andrés Íñiguez-Romo

Collaboration


Dive into the Francisco Calvo-Iglesias's collaboration.

Top Co-Authors

Avatar

Andrés Íñiguez-Romo

University Hospital Complex Of Vigo

View shared research outputs
Top Co-Authors

Avatar

Emad Abu-Assi

University of Santiago de Compostela

View shared research outputs
Top Co-Authors

Avatar

José Antonio Baz-Alonso

University Hospital Complex Of Vigo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alberto Dominguez-Rodriguez

Hospital Universitario de Canarias

View shared research outputs
Top Co-Authors

Avatar

Alberto Garay

Bellvitge University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge